A Phase 3 interventional study of Magnesium Sulfate and Nifedipine in Placenta Previa, sponsored by Assiut University. Completed at 1 site in Egypt. Open to female participants. Per ClinicalTrials.gov, last updated 2021-07-28.
Sponsored by Assiut University · Phase 3, Interventional, and Prevention
Antepartum hemorrhage is defined as bleeding from or within the female genital tract, occurring from 28+0 weeks of pregnancy and till delivery of the fetus. it occurs in 3-5% of pregnancies and is an important cause of perinatal and maternal morbidity and mortality worldwide
There are many tocolytic agents may have a role in conservative management of placenta previa such as magnesium sulfate, calcium channel blockers and β-sympathormimetics. In 2004 Sharma suggests that ritodrine hydrochloride in patients with symptomatic placenta previa tends to prolong the pregnancy and result in an increase in birth weight of the babies without causing any adverse effect on the mother and fetus
80 studies on the registry are indexed under Placenta Previa; 17 are open to participants now.
This study's enrollment of 176 is above the median of 109 across 45 interventional studies indexed under Placenta Previa.
Browse Placenta Previa studies →Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
received oral nifedipine 10 mg every 20 minutes for three doses, followed by 10 mg orally every 6 hours
Drug: Nifedipine
Patients in the MgSO4 group received intravenous 6 g bolus MgSO4 20% followed by a 2 g/h infusion
Drug: Magnesium Sulfate
Patients received intravenous 6 g bolus MgSO4 20% followed by a 2 g/h infusion
received oral nifedipine 10 mg every 20 minutes for three doses, followed by 10 mg orally every 6 hours
The duration of prolongation of gestation
measured from the time of enrollment to the time of delivery
Time frame: 1 month
Ran from Jun 2018 to primary completion in Mar 2021, 33 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Magnesium Sulfate